Prothena reported $11.43M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Exelixis USD 411.88M 49.95M Sep/2026
Immunic USD 31.55M 290K Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Prothena USD 11.43M 224K Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026